£138.18
1.54%
London, Nov 17, 12:17 pm GMT. Market open.
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock News

Negative
●
Barrons
●
about 23 hours ago
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Neutral
●
Business Wire
●
4 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's ​IMFINZI® (durvalumab)​ in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have...
Negative
●
Reuters
●
4 days ago
AstraZeneca has cut about 600 ​jobs from its respiratory and ‌immunology commercial teams in the US as part of its three-year cost-savings initiative, ​Bloomberg News reported on Friday, citing ​people familiar with the matter.
Positive
●
Reuters
●
4 days ago
AstraZeneca said on Friday a European medicines committee had backed its ​hypertension pill baxdrostat, branded as Baxfendy, ‌for marketing authorisation, potentially making it the first drug of its class to reach ​patients in the European Union.
Neutral
●
Business Wire
●
7 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative. The initiative supports programs that prioritize the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. Through the 6th annual Community S...
Neutral
●
Business Wire
●
7 days ago
ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose...
Positive
●
WSJ
●
13 days ago
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today